AURINIA PHARMACEUTICALS INC

Zymeworks Inc.’s cancer drug zanidatamab (Ziihera) received FDA approval for treating biliary-tract cancer, marking a milestone in the company’s recovery. The drug is the first bispecific antibody and chemotherapy-free treatment for metastatic HER2-positive BTC. Zymeworks, which faced a corporate crisis in 2022, has partnered with Jazz Pharmaceuticals for North America, Europe, and Japan, and with BeiGene Ltd. for other Asian markets. The approval unlocks potential peak global sales of US$55-million, with further trials potentially expanding this to US$750-million. Zymeworks is eligible for up to US$500-million in milestone payments from Jazz and royalties of 10-20% on net sales.

The global oral proteins and peptides market is projected to reach USD 20.36 billion by 2029, driven by increasing demand for oral peptides in treating chronic diseases, R&D investments, and advancements in drug delivery technologies. The US dominates the market, supported by a strong biopharmaceutical sector and presence of key players like Novo Nordisk and Pfizer. Semaglutide leads in molecule segments, used for managing type-2 diabetes and obesity.

Chapters cover methodology, executive summary, market variables, segmentation by disease, molecule, biological target, mechanism, and region, and competitive landscape.

Aurinia Pharmaceuticals announces Japanese approval of voclosporin, in combination with mycophenolate mofetil, for treating lupus nephritis, based on the AURORA Clinical Program data.